NCT00702351 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Fatemi HM, Oberyé J, Popovic-Todorovic B, Witjes H, Mannaerts B, Devroey P
Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial. Fertil Steril. 2010 Oct;94(5):1922-4. doi: 10.1016/j.fertnstert.2009.12.070. Epub 2010 Feb 10.

A Phase II, Uncontrolled Pilot Trial to Evaluate That a Single Dose of 100 μg or 150 μg Org 36286 (Corifollitropin Alfa) is Able to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI Using a Long Protocol of GnRH Agonist (Study 38833)

Details for clinical trial NCT00702351

Clinical trial NCT00702351 - References